Acute treatment (Study 1) (n = 16) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Control session | DSCD session | pi | pi−2 | pi−3 | |||||
Before | After | p-value | Before | After | p-value | ||||
Reactive hyperaemia index | 1.90 ± 0.50 | 2.11 ± 0.40 | 0.176 | 2.07 ± 0.33 | 2.22 ± 0.48 | 0.298 | 0.839 | 0.874 | NA |
Chronic treatment (study 2) (n = 38) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Control period | DSCD period | pi | pi−2 | pi−3 | |||||
Before | After | p-value | Before | After | p-value | ||||
Brachial artery diameter (mm) | 3.91 ± 0.60 | 3.97 ± 0.65 | 0.547 | 4.00 ± 0.67 | 3.96 ± 0.57 | 0.527 | 0.332 | 0.332 | 0.165 |
FMD (%) | 4.38 ± 2.09 | 4.17 ± 2.11 | 0.579 | 3.78 ± 1.67 | 3.76 ± 2.05 | 0.961 | 0.670 | 0.678 | 0.490 |
VTI (cm) | 81.0 ± 21.0 | 84.3 ± 23.0 | 0.338 | 80.7 ± 22.0 | 84.8 ± 21.7 | 0.161 | 0.851 | 0.855 | 0.479 |
SSRH (dyn/cm2) | 67.8 ± 20.6 | 67.9 ± 22.2 | 0.895 | 66.7 ± 19.5 | 70.4 ± 23.7 | 0.246 | 0.431 | 0.433 | 0.229 |